Teva UK Enters Erectile Dysfunction Category With First Ever Rx-To-OTC Switch
Executive Summary
Teva UK's first Rx-to-OTC switch is a UK Viagra Connect sildenafil competitor under the Liberize brand. Priced around 25% lower than the market leader, Teva's new brand must also compete with Perrigo's white label and Dr Reddy's Almus branded alternatives within the country's growing erectile dysfunction category.
You may also be interested in...
‘Meaningful Revenues’ In 2023 Mark Strategic Milestone As Futura Looks To Future
Futura recorded its first notable revenues last year, generated by the launch of its Eroxon erectile dysfunction gel in the UK and Europe, marking the company's transition from an R&D startup to a consumer healthcare player in its own right. To mark the occasion, CEO James Barder outlines a new strategy, with a focus on innovation in sexual wellness, further global partnerships and sustained profitability.
USP And Dexcel Pick Up Teva OTC Brands
Teva has struck a deal with USP in Poland that will see the Israeli company divest multiple consumer health brands. Meanwhile, Dexcel Pharma has acquired eight OTC brands from Teva in the UK.
UK’s Dexcel Pharma Snaps Up Eight OTC Brands From Teva
Dexcel Pharma has acquired eight OTC brands from Teva, including Bisodol Indigestion Relief Tablets, erectile dysfunction treatment Liberize and Yeast Vite supplements. Teva told HBW Insight it remains committed to the consumer health market despite a number of recent brand divestments.